Socio-economic burden of disease: survivorship costs for renal cell carcinoma

• Verfasst von: Michaeli, Julia [VerfasserIn]
• Verfasst von: Michaeli, Daniel [VerfasserIn]
• Verfasst von: Boch, Tobias [VerfasserIn]
• Verfasst von: Albers, Sebastian [VerfasserIn]
• Verfasst von: Michaeli, Christoph T. [VerfasserIn]
• Titel: Socio-economic burden of disease: survivorship costs for renal cell carcinoma
• Verf.angabe: Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli
• E-Jahr: 2022
• Jahr: May 2022
• Umfang: 11 S.
• Fussnoten: Erstmals veröffentlicht: 15. März 2022 ; Gesehen am 27.02.2024
• Titel Quelle: Enthalten in: European journal of cancer care
• Ort Quelle: London : Hindawi Limited, 1992
• Jahr Quelle: 2022
• Band/Heft Quelle: 31(2022), 3 vom: Mai, Artikel-ID e13569, Seite 1-11
• ISSN Quelle: 1365-2354
• DOI: doi:10.1111/ecc.13569
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cancer survivors
• Sach-SW: cost of illness
• Sach-SW: health expenditure
• Sach-SW: health insurance
• Sach-SW: renal cell carcinoma
• Sach-SW: survivorship
• K10plus-PPN: 1881652157

Abstract

Objective The objective of this study is to assess the risk-stratified 10-year socio-economic burden of renal cell carcinoma (RCC) follow-up costs after initial treatment in Germany from 2000 to 2020. Methods A micro-costing method considering direct and indirect medical expenditure associated with follow-up procedures was employed to calculate survivorship costs per patient. The frequencies of physician-patient visits, examinations and diagnostic tests were extracted from guidelines, whilst expenses were sourced from literature and official scales of tariffs. Societal costs were calculated based on three perspectives: patients, providers and insurers. Results Mean societal 10-year follow-up costs per patient amounted to EUR 3,377 (95%CI: 2,969-3,791) for low-risk, EUR 3,367 (95%CI: 3,003-3,692) for medium-risk and EUR 4,299 (95%CI: 3,807-4,755) for high-risk RCC in 2020. Spending increased by +32% from 2000 to 2020 for low-risk RCC, whilst medium-and high-risk RCC expenditure was cut by −39% and −22%, respectively. Patients shouldered 27%, providers 43% and insurers 35% of costs in 2020. Resources were consumed by medical imaging (52%), physician-patient consultations (31%), travel expenses (17%) and blood tests (1%). Conclusion Results highlight the economic burden cancer survivorship poses for society. Cancer survivors require individualised, evidence-based and insurance-covered follow-up schedules to permit the early detection of side-effects, metastasis and secondary malignancies.